Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

450 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia.
Bibawi S, Abi-Said D, Fayad L, Anderlini P, Ueno NT, Mehra R, Khouri I, Giralt S, Gajewski J, Donato M, Claxton D, Braunschweig I, van Besien K, Andreeff M, Andersson BS, Estey EH, Champlin R, Przepiorka D. Bibawi S, et al. Among authors: gajewski j. Am J Hematol. 2001 Aug;67(4):227-33. doi: 10.1002/ajh.1121. Am J Hematol. 2001. PMID: 11443634 Free article. Clinical Trial.
The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy.
Cheng YC, Rondón G, Yang Y, Smith TL, Gajewski JL, Donato ML, Shpall EJ, Jones R, Hortobagyi GN, Champlin RE, Ueno NT. Cheng YC, et al. Among authors: gajewski jl. Biol Blood Marrow Transplant. 2004 Nov;10(11):794-804. doi: 10.1016/j.bbmt.2004.07.009. Biol Blood Marrow Transplant. 2004. PMID: 15505610 Free article. Clinical Trial.
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation.
Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M, Hosing C, Anderlini P, Donato M, Cleary K, Gajewski J, Neumann J, Ippoliti C, Rondon G, Cohen A, Champlin R. Couriel DR, et al. Among authors: gajewski j. Biol Blood Marrow Transplant. 2004 Mar;10(3):178-85. doi: 10.1016/j.bbmt.2003.10.006. Biol Blood Marrow Transplant. 2004. PMID: 14993883 Free article.
Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation.
de Lima M, Anagnostopoulos A, Munsell M, Shahjahan M, Ueno N, Ippoliti C, Andersson BS, Gajewski J, Couriel D, Cortes J, Donato M, Neumann J, Champlin R, Giralt S. de Lima M, et al. Among authors: gajewski j. Blood. 2004 Aug 1;104(3):865-72. doi: 10.1182/blood-2003-11-3750. Epub 2004 Apr 15. Blood. 2004. PMID: 15090449 Free article.
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.
Wong R, Shahjahan M, Wang X, Thall PF, De Lima M, Khouri I, Gajewski J, Alamo J, Couriel D, Andersson BS, Donato M, Hosing C, Komanduri K, Anderlini P, Molldrem J, Ueno NT, Estey E, Ippoliti C, Champlin R, Giralt S. Wong R, et al. Among authors: gajewski j. Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14. doi: 10.1016/j.bbmt.2004.10.008. Biol Blood Marrow Transplant. 2005. PMID: 15682071 Free article.
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, Anderlini P, de Lima M, Gajewski J, Champlin RE. Andersson BS, et al. Among authors: gajewski j. Biol Blood Marrow Transplant. 2002;8(9):477-85. doi: 10.1053/bbmt.2002.v8.pm12374452. Biol Blood Marrow Transplant. 2002. PMID: 12374452 Free article. Clinical Trial.
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias.
de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, Khouri I, Gajewski J, van Besien K, Champlin R, Giralt S, Kantarjian H. de Lima M, et al. Among authors: gajewski j. Cancer. 2003 Mar 1;97(5):1242-7. doi: 10.1002/cncr.11184. Cancer. 2003. PMID: 12599231 Free article. Clinical Trial.
Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.
van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas FF, Champlin R. van Besien KW, et al. Among authors: gajewski jl. Am J Med. 1996 Mar;100(3):299-307. doi: 10.1016/S0002-9343(97)89488-0. Am J Med. 1996. PMID: 8629675
450 results